broker recommendation, page-129

This not ZIP where over ambitious global expansion , with little to differentiate among a surplus of providers , worked against it once interest rates rose ( its still surviving and looking to be profitable next year after selling off and withdrawing from most countries so not knocking the stock) . This is a highly defensive stock in terms of product with huge growth possibilities. The treatment itself is used in ever more different scenarios and is a necessity in a world of increasing pop density in cities. Its affordability and low overall medical costs from product to medical care a big market plus. I am not dismissing valid concerns that the company keep a tight reign on risks but if it say withdrew from say India in the next 12 months it could be managed , so hardly fatal. Swami and DW would be grossly negligent if they were not cognizant of market concerns and caution re risks so one assumes as experienced operators having survived a brutal ,long period, share wise, that they will be keeping close tabs on any investment decisions AND monitoring these.